3,3′-Diindolylmethane Enhances the Efficacy of Butyrate in Colon Cancer Prevention through Down-regulation of Survivin

doi:10.1158/1940-6207.CAPR-08-0142

Cancer Prev Res (Phila). Author manuscript; available in PMC 2010 July 9.

Published in final edited form as:

Cancer Prev Res (Phila). 2009 June; 2(6): 581–589.

Published online 2009 May 26. doi: 10.1158/1940-6207.CAPR-08-0142

PMCID: PMC2901098

NIHMSID: NIHMS209111

3,3′-Diindolylmethane Enhances the Efficacy of Butyrate in Colon Cancer Prevention through Down-regulation of Survivin

Namrata Bhatnagar,^1,³ Xia Li,^1,³ Yue Chen,¹ Xudong Zhou,² Scott H. Garrett,² and Bin Guo¹^*

¹Department of Pharmaceutical Sciences, College of Pharmacy, North Dakota State University, Fargo, ND 58105

²Department of Pathology, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, North Dakota 58202

^* Requests for reprints: Bin Guo, Department of Pharmaceutical Sciences, College of Pharmacy, North Dakota State University, Fargo, ND 58105. Phone: 701-231-5164; Fax: 701-231-8333; Email: Bin.Guo/at/ndsu.edu

³These authors contributed equally to this work.

The publisher's final edited version of this article is available at Cancer Prev Res (Phila)

See other articles in PMC that cite the published article.

Abstract

Butyrate is an inhibitor of histone deacetylase (HDAC) and has been extensively evaluated as a chemoprevention agent for colon cancer. We recently demonstrated that mutations in the adenomatous polyposis coli (APC) gene confer resistance to HDAC inhibitor-induced apoptosis in colon cancers (Huang and Guo, Cancer Research, 66(18), 9245-9251, 2006). Here we show that APC mutation rendered colon cancer cells resistant to butyrate-induced apoptosis due to the failure of butyrate to down-regulate survivin in these cells. Another cancer preventive agent, 3,3′-Diindolylmethane (DIM), was identified to be able to down-regulate survivin in colon cancers expressing mutant APC. DIM inhibited survivin mRNA expression and promoted survivin protein degradation through inhibition of p34^cdc2-cyclin B1-mediated survivin Thr34 phosphorylation. Pre-treatment with DIM enhanced butyrate-induced apoptosis in colon cancer cells expressing mutant APC. DIM/butyrate combination treatment induced the expression of pro-apoptotic Bax and Bak proteins, triggered Bax dimerization/activation, and caused release of cytochrome c and Smac proteins from mitochondria. While overexpression of survivin blocked DIM/butyrate-induced apoptosis, knocking-down of survivin by siRNA increased butyrate-induced apoptosis in colon cancer cells. We further demonstrated that DIM was able to down-regulate survivin and enhance the effects of butyrate in apoptosis induction and prevention of familial adenomatous polyposis in APC^min/+ mice. Thus, the combination of DIM and butyrate is potentially an effective strategy for the prevention of colon cancer.

Keywords: 3,3′-Diindolylmethane, Butyrate, Survivin, Apoptosis, Adenomatous Polyposis Coli

Introduction

Colon cancer is one of the leading causes of cancer death in developed countries. A large number of pre-clinical studies have examined various agents for the prevention of colon cancer. However, significant tumor suppression activity was rarely observed, and tumor occurrence even increased after treatment in certain cases ¹^,². Butyrate is produced naturally in the colon by bacterial fermentation of dietary fibers and has been extensively studied in colon cancer prevention. Butyrate inhibits tumor growth and induces apoptosis through the inhibition of histone deacetylases (HDAC) ³^,⁴. Histone deacetylases together with histone acetyltransferases regulate the acetylation of core nucleosomal histones, which is important for the transcription activity of the target genes ⁵. Abnormal HDAC activity has been associated with the development of many types of cancer ⁶. HDAC inhibitors induce differentiation, growth arrest, and apoptosis in cancer cells, while they are relatively nontoxic to normal cells ⁶^-⁸. As an HDAC inhibitor, butyrate is a promising prevention agent for colon cancer ⁹^,¹⁰. However, the activity of butyrate has been moderate in chemoprevention studies using animal models ¹¹^-¹³. For a potential explanation of the ineffectiveness of butyrate, we recently demonstrated that mutations in the adenomatous polyposis coli (APC) gene in colon cancers can confer resistance to HDAC inhibitor-induced apoptosis ¹⁴.

Colon cancer is caused by the accumulation of mutations in a number of oncogenes and tumor suppressor genes. APC, deleted in colon cancer (DCC), K-Ras, and p53 are among the most frequently mutated genes in colon cancer ¹⁵^-¹⁸. APC is a key component of the β-catenin destruction complex (consisting GSK-3β, axin, and APC) and involved in the Wnt signaling pathway ¹⁹. Axin and APC form a structural scaffold that allows GSK-3β to phosphorylate β-catenin. Phosphorylated β-catenin is subsequently degraded by the proteasome ¹⁹. Loss of wild-type APC expression results in the nuclear accumulation of β-catenin, which interacts with Tcf-4/Lef1 transcription factors to cause aberrant gene transcription and formation of cancer ²⁰^,²¹. The role of APC as a tumor suppressor has been further demonstrated in mice with APC mutations which develop multiple intestinal neoplasia (APC^min/+ mice) ²²^,²³.

Previous studies in our lab have shown that resistance to HDAC inhibitors by colon cancers expressing mutant APC was due to a failure to down-regulate survivin ¹⁴. Survivin is an anti-apoptotic protein of the inhibitor of apoptosis (IAP) family. Survivin is expressed at high level in many types of cancers, but not in normal tissues from the same organs ²⁴. Survivin blocks apoptosis by inhibiting caspases and antagonizing mitochondrial-dependent apoptosis ²⁴. Survivin also regulates cell division through interaction with INCENP and Aurora B kinase ²⁵.

3,3′-Diindolylmethane (DIM) is a non-toxic cancer-preventive phytonutrient isolated from broccoli and cabbage. The anti-cancer activity of DIM was linked with inhibition of mitochondrial H(+)-ATP synthase and induction of p21(Cip1/Waf1) expression in breast cancer cells ²⁶, down-regulation of androgen receptor ²⁷ and inhibition of mammalian target of rapamycin (mTOR) ²⁸ in prostate cancer cells, inhibition of AKT signaling and FLICE-like inhibitory protein in cholangiocarcinoma cells ²⁹, activation of caspase-8 in colon cancer cells ³⁰, as well as inactivation of NF-kappaB ³¹ and down-regulation of survivin in breast cancer cells ³². DIM was also shown to inhibit angiogenesis and invasion by repressing the expression of matrix metalloproteinase MMP-9 and urokinase-type plasminogen activator (uPA) ³³.

In the present study, we found that colon cancer cells expressing mutant APC are resistant to butyrate-induced apoptosis due to the failure to down-regulate survivin. Importantly, we shown that DIM was able to down-regulate survivin and potentiate butyrate-induced apoptosis in these resistant cells. DIM can be used to enhance the efficacy of butyrate in colon cancer prevention.

Materials and Methods

Cells and Transfection

Human colon cancer cell line HT-29 was purchased from American Type Culture Collection. The cells were cultured in Dulbecco's Modified Eagle Medium containing 10% fetal bovine serum. Human colon cancer HT-29/APC and HT-29/β-Gal cells were generously provided by Dr. Vogelstein of Johns Hopkins University and cultured as described ³⁴. IMCE cells were kindly provided by Dr. Robert H. Whitehead of Vanderbilt University and cultured at 33°C, in RPMI1640 media containing 5% fetal calf serum, 1 μg/ml insulin, 10^-5M α-thioglycerol and 5 units/ml of mouse gamma interferon. For transient transfection, plasmids were transfected into cells using Lipofectamine™Plus Reagent (Invitrogen) following the manufacturer's protocol.

Drugs and Chemicals

Butyrate was purchased from Sigma (St. Louis, MO) and dissolved in phosphate-buffered saline (PBS) at concentration of 400 mM. 3,3′-Diindolylmethane was purchased from LKT Laboratories (St. Paul, MN) and dissolved in dimethylsulfoxide (DMSO) at concentration of 40 mM. In all studies, an equivalent amount of diluent (DMSO or PBS) was added to culture media as a negative control. Proteasome inhibitor MG-132 was purchased from Calbiochem (San Diego, CA) and dissolved in DMSO at concentration of 10 mM. Cycloheximide was obtained from Sigma (St. Louis, MO) and dissolved in DMSO at concentration of 355 mM. Disuccinimidyl suberate (DSS) was purchased from Pierce (Rockford, IL).

Plasmids Construction

Human cDNA encoding full-length survivin gene was obtained by PCR amplification using an EST clone (I.M.A.G.E. clone ID 4477581) as template. Survivin cDNA was sub-cloned into phrGFP-C and pCMV-Tag2A expression vectors (Stratagene).

Detection of Apoptosis

In TUNEL assay, cells were fixed with 1% paraformaldehyde on ice for 1h and then washed with PBS and permeabilized with 70% ethanol at -20 °C for 12h. Cells were then labeled with Guava^® TUNEL Assay reagents and analyzed on the Guava PCA microcytometer following the manufacturer's protocol. In 4′,6-diamidine-29-phenylindole dihydrochloride (DAPI) staining, GFP or GFP-survivin expressing cells were fixed with PBS containing 3.7% formaldehyde, and stained with 0.5 μg/ml DAPI in PBS. The percentages of apoptotic cells were determined by confocal microscopy, counting GFP-positive cells having nuclear fragmentation and/or chromatin condensation. In the Elisa assay, the Cell Death Detection Elisa^PLUS kit (Roche) was used following the manufacturer's protocol. This assay determines apoptosis by measuring mono- and oligonucleosomes in the lysates of apoptotic cells. The cell lysates were placed into a streptavidin-coated microplate and incubated with a mixture of anti-histone-biotin and anti-DNA-peroxidase. The amount of peroxidase retained in the immunocomplex was photometrically determined with ABTS as the substrate. Absorbance was measured at 405 nm.

Western Blot Analysis

Cells were lysed in RIPA buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS in PBS). Complete protease inhibitor cocktail (Roche) was added to lysis buffer before use. Protein concentration was determined by Bio-Rad DC protein assay (Bio-Rad). Protein samples were subjected to SDS-PAGE and transferred to nitrocellulose membrane. The membrane was blocked in 5% non-fat milk in PBS overnight and incubated with primary antibody and subsequently with appropriate horse radish peroxidase-conjugated secondary antibody. Signals were developed with ECL reagents (Amersham) and exposure to X-ray films. Image digitization and quantification were performed with UN-SCAN-IT software from Silk Scientific (Orem, UT). Anti-survivin, anti-Cdc2, anti-Cyclin B1, anti-Bax, and anti-β-tubulin monoclonal antibodies, and anti-Bak polyclonal antibodies were purchased from Santa Cruz Biotechnology. Anti-hrGFP monoclonal antibody was purchased from Stratagene. Anti-Smac monoclonal antibody and anti-cleaved caspase-3, anti-cleaved caspase-7, anti-cleaved caspase-9, anti-HDAC1, anti-HDAC2, anti-HDAC3, anti-HDAC4, anti-HDAC5, anti-HDAC7, and anti-cleaved PARP polyclonal antibodies were purchased from Cell Signaling Technology. Anti-phospho-survivin (Thr34) polyclonal antibody was purchased from Novus. Anti-Hsp60 monoclonal antibody was purchase from BD Biosciences. APC protein was detected by western blot as described previously ¹⁴. Anti-APC monoclonal antibody was purchased from Calbiochem.

Cross-linking Study

DSS was dissolved in DMSO at 25 mM concentration. Before protein isolation for western blot, cells were treated with 1 mM DSS in PBS for 30 min at 37°C. The stop solution (1 M Tris, pH 7.5) was then added to a final concentration of 10 mM and incubated for 15 min. Total protein was isolated and western blot was performed as described above.

Subcellular Fractionation

Cells (20 × 10⁶) were harvested by centrifugation at 600 × g for 10 min at 4°C. The cell pellets were washed once with ice-cold PBS and resuspended with 5 volumes of buffer A (20 mM HEPES-KOH, pH 7.5, 10 mM KCI, 1.5 mM MgCI₂, 1 mM sodium EDTA, 1 mM sodium EGTA, 1 mM dithiothreitol, and 0.1 mM phenylmethylsulfonylfluoride) containing 250 mM sucrose. Cells were homogenized with 10 strokes of a Teflon homogenizer, and centrifuged twice at 750 × g for 10 min at 4°C. Supernatants were centrifuged at 10,000 × g for 20 min at 4°C. The resulting mitochondria pellets were resuspended in buffer A and frozen at -80°C for future use. The supernatants of the 10,000 × g spin were further centrifuged at 100,000 × g for 1 h at 4°C, and the resulting supernatants were designated cytosol fraction and stored at -80°C.

siRNAs and Transfection

Silencer™ validated siRNAs and negative control siRNA (Cat# 4611) were purchased from Ambion (Austin, TX). The sequence for survivin siRNA is: sense (5′-GGAACAUAAAAAGCAUUCGtt-3′) and antisense (5′-CGAAUGCUUUUUAUGUUCCTC -3′). Survivin siRNA was transfected into HT-29 cells using X-tremeGENE siRNA transfection reagent (Roche) following the manufacturer's protocol. Cells were cultures and transfected in 6-well plates (1×10⁵ cells per well) and the final siRNA concentration was 100 nM. Protein samples were collected at 48h after transfection for western blot analysis. For apoptosis assay, drugs were added at 24h after siRNA transfection and cells were collected at 72h post transfection.

Real-time PCR

The mRNA level of survivin was measure by real-time PCR using TaqMan® Gene Expression assay (Cat # Hs00153353) from Applied Biosystems (Foster city, CA). Total RNA was isolated from HT-29 cells using RNeasy® kit (Qiagen). 5 μg of total RNA was used in reverse transcription reaction. The cDNAs were used as templates to perform PCR on an Applied Biosystems 7500 Real-time PCR System following the manufacturer's protocol.

APC^min/+ Mice and Treatment

APC^min/+ mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Mice were housed in an animal-holding room under controlled light, temperature and humidity and were fed Purina lab rodent diet (LabDiet 5K20) and water ad libitum. All procedures were approved by the Institutional Animal Care and Use Committee of North Dakota State University. For treatment, APC^min/+ mice were separated into four groups (5 each): control group, butyrate group, DIM group, and DIM/butyrate combination group. Treatment began at six weeks of age. For DIM and DIM/butyrate group, DIM was administered in drinking water at a calculated dose of 10 mg/kg/day on days 1, 3, and 5 during week six. Butyrate was administered in drinking water for one week, at a calculated dose of 24 mg daily, starting on day 1 of week six for the butyrate group and on day 7 of week six for the DIM/butyrate group. Calculation of the doses was done as shown in the following example: a 20 gram mouse drinks about 3ml water per day ³⁵; 10 mg/kg equals to a dose of 0.067 mg/ml of DIM in water. Mice in the control group were treated with regular water. The mice were weighed twice weekly and monitored daily for signs of weight loss or lethargy that might indicate intestinal obstruction or anemia. At 16 weeks of age, Mice were euthanized by pentobarbital injection (200 mg/kg) and cervical dislocation. After necropsy, the intestinal tracts were dissected from the esophagus to the distal rectum, spread onto filter paper, opened longitudinally with fine scissors, and cleaned with sterile saline. Tumor counts were performed under a dissection microscope with ×5 magnification. For in vivo apoptosis detection, separate groups of mice were treated with doses and schedule as above and sacrificed at 24 hours after the last dose of treatments and the tumor specimens were fixed in formalin.

In vivo Apoptosis Detection

The apoptotic cells in tumors were detected using an ApopTag In situ Apoptosis Detection kit (Chemicon). The assay was done according to the manufacturer's protocol. Tumor were fixed in 10% neutral-buffered formalin, dehydrated, and embedded in paraffin. After deparaffinization, the tissue sections were pretreated with proteinase K and then incubated with terminal deoxynucleotidyl transferase enzyme at 37°C for 1 h, washed thrice with PBS, and incubated with antidigoxigenin conjugate in a humidified chamber at room temperature for 30 min. The color was developed by incubating the sections with peroxidase substrate. Apoptosis indices were calculated as the percentage of apoptotic cells among 1000 tumor cells in a randomly selected nonnecrotic portion of the tumor.

Statistical Analysis

Differences between the mean values were analyzed for significance using the unpaired two-tailed Student's test for independent samples; P ≤0.05 was considered to be statistically significant.

Results

APC mutation causes failure of survivin down-regulation and confers resistance to butyrate-induced apoptosis

Butyrate has been extensively studied as a cancer prevention agent for colon cancers, but with only limited activity observed ¹¹^-¹³. We have previously shown that mutations in the APC gene (which occur in over 85% of sporadic colon cancers) render colon cancer cells resistant to HDAC inhibitors ¹⁴. Since butyrate acts as a HDAC inhibitor, we hypothesize that APC mutations may also cause resistance to butyrate-induced apoptosis. To determine whether APC plays a role in colon cancer cell apoptosis in response to butyrate, we compared butyrate-induced apoptosis in HT-29/β-Gal and HT-29/APC cells. HT-29 colon cancer cells express two C-terminal-truncated mutant APC proteins. HT-29/APC are genetically engineered HT-29 cells in which wild-type APC is expressed from a Zn²⁺-inducible transgene ³⁴. Expression of APC induces apoptosis in HT-29 cells ³⁴. To avoid apoptosis induce by APC expression alone, we used 50 μM Zinc to induce APC expression ¹⁴. After induction of wild-type APC, apoptosis was observed in HT-29/APC cells when treated with butyrate (Fig. 1A). In contrast, the HT-29/β-Gal cells were resistant. When Zn²⁺ was not added to the culture media to induce APC expression, HT-29/APC cells showed comparable resistance to butyrate-induced apoptosis (data not shown). We have previously demonstrated that a failure to down-regulate survivin is the key mechanism of APC mutation-induced resistance to HDAC inhibitors ¹⁴. To further understand the mechanism of APC-mediated apoptosis after butyrate treatment, we examined the expression of survivin. Down-regulation of survivin was observed in HT-29/APC cells after induction of APC expression and treatment with butyrate, but not in HT-29/β-Gal cells (Fig. 1B). Since HT-29 cell lines express mutant p53 proteins, the down-regulation of survivin appears to be p53-independent.

Figure 1

Butyrate down-regulates survivin and induces apoptosis in HT-29/APC cells, but not in HT-29/β-Gal cells

3,3′-Diindolylmethane down-regulates survivin in HT-29 cell

Since APC is frequently mutated in colon cancer patients, the data above predicts the ineffectiveness of butyrate in preventing colon cancers. To overcome resistance to butyrate-induced apoptosis in APC mutant tumors, we tested various agents (including Genistein, selenium, DIM, and others) to identify a non-toxic agent that can down-regulate survivin. We found that DIM, a cancer prevention agent from food plants including cabbage and broccoli, was able to down-regulate survivin in HT-29 cells. Treatment with DIM down-regulated survivin in a dose-dependent manner (Figure 2A). We determined whether down-regulation of survivin by DIM occurred at transcription level. Using real-time PCR, we found that treatment with 40 μM DIM for 24 hours decreased survivin mRNA level by 53% in HT-29 cells, compared to untreated cells (Figure 2B). Next, we determined whether proteasome-dependent degradation is also involved in the down-regulation of survivin in response to DIM. As shown in Figure 2C, co-treatment with a proteasome inhibitor MG-132 (10 μM) completely blocked the DIM-induced down-regulation of survivin protein in HT-29 cells. To determine if DIM promotes the degradation of survivin protein, HT-29 cells were treated with 20 μM cycloheximide or 20 μM cycloheximide plus 40 μM DIM, degradation of survivin was determined by western blotting. DIM exposure promoted survivin degradation in HT-29 cells (Figure 2D). The stability of survivin protein is maintained by p34^cdc2-cyclin B1 phosphorylation on Thr34 of the protein, and Thr34 dephosphorylation causes survivin degradation ³⁶^,³⁷. To further determine the mechanism of DIM-promoted survivin degradation, we examined the effects of DIM on p34^cdc2 and cyclin B1. As shown in Figure 2E, DIM treatment caused a significant decrease of cyclin B1 protein level in a dose-dependent manner, while the p34^cdc2 level remained unchanged. As a result, survivin Thr34 phosphorylation was decreased after DIM treatment (Figure 2F), contributing to the decreased stability of survivin. This result indicates that DIM causes survivin degradation independent of wild-type APC, through a mechanism involving decreased survivin Thr34 phosphorylation by p34^cdc2-cyclin B1.

Figure 2

3,3′-Diindolylmethane down-regulates survivin in HT-29 cells

3,3′-Diindolylmethane enhances butyrate-induced apoptosis in HT-29 cells

Since DIM is able to down-regulate survivin in HT-29 cells, we tested whether DIM can help overcome APC mutation-mediated resistance to butyrate-induced apoptosis. Pre-treatment with 40 μM DIM significantly enhanced butyrate-induced apoptosis in HT-29 cells (Figure 3A). DIM alone at this dose did not induce significant level of apoptosis. To identify the key mediators of DIM/butyrate-induced apoptosis, HT-29 cells were treated with DIM, butyrate, or DIM/butyrate combination. Western blot analysis with various antibodies identified significantly higher levels of cleaved (activated) caspase-7 and cleaved (activated) caspase-9 in DIM/butyrate-treated cells (Figure 3B), indicating these two caspases potentially mediate apoptosis in the combination treatment. We did not observe caspase-3 activation in these treatments (data not shown). Interestingly, the combination of DIM and butyrate was synergistic in causing survivin down-regulation (Figure 3B). We also determined the effects of DIM on the expression level of HDAC proteins in HT-29 cells. As shown in Figure 3C, DIM treatment induced significant decreases in the levels of class I HDACs (HDAC1, HDAC2, HDAC3) in a dose-dependent manner. However, DIM had no effects on the levels of class II HDACs (HDAC4, HDAC5, and HDAC7) (Figure 3C and data not shown). By down-regulating the HDAC proteins, DIM should enhance the effects of butyrate on HDAC inhibition. To further understand the mechanisms of how DIM increases butyrate-induced apoptosis in HT-29 cells, we examined the effects of DIM/butyrate combination on the key apoptosis regulators Bax and Bak. Bax and Bak double knockout mice displayed developmental defects in multiple tissues, indicating that Bax and Bak are critical apoptosis regulators ³⁸. Deletion of both Bax and Bak also results in resistance to various apoptotic stimuli known to trigger mitochondria-dependent apoptosis ³⁹. In contrast, the BH3-only proteins of the Bcl-2 family (Bid, Bad etc.) are signal transducers and they require Bax or Bak to induce apoptosis ³⁹^,⁴⁰. We found that the DIM/butyrate combination treatment caused significant increases of both Bax and Bak proteins, as well as the dimerization of the 21 kd monomer Bax into 42 kd dimers (representing the activated Bax, ⁴¹^,⁴²) (Figure 3D). Activation of Bax and Bak may facilitate or directly cause the release of pro-apoptotic mitochondrial proteins into cytosol. To test this hypothesis, the localization of cytochrome c and Smac proteins was determined by subcellular fractionation experiments. As shown in Figure 3E, the DIM/butyrate combination caused significant release of cytochrome c and Smac proteins from the mitochondria of HT-29 cells. Cytochrome c together with Apaf-1 promote apoptosome formation and activation of pro-caspase-9 ⁴³^,⁴⁴ while Smac antagonizes the activities of inhibitor of apoptosis proteins (IAPs) and activates caspases ⁴⁵, which explain the observed activation of caspases and apoptosis in HT-29 cells (Figure 3A and 3B).

Figure 3

3,3′-Diindolylmethane enhances butyrate-induced apoptosis in HT-29 cells

Survivin plays a key role in DIM/butyrate-induced apoptosis

We understand that survivin is not the only target of DIM. However, survivin may play a key role in the apoptotic effects observed during DIM/butyrate combination treatment. To determine the role of survivin, we overexpressed survivin protein in HT-29 cells by transient transfection. As shown in Figure 4A, overexpression of survivin blocked DIM/butyrate-induced apoptosis in HT-29 cells. Furthermore, knocking-down survivin by siRNA sensitized HT-29 cells to butyrate-induced apoptosis (Figure 4B). These data suggest that despite survivin is not the only target of DIM, it plays a critical role in DIM's activity when in combination with butyrate. Down-regulation of survivin by DIM lowers the threshold of apoptosis induction and allows the activation of downstream mechanisms of apoptosis (such as Bax activation, cytochrome c / Smac release, and activation of caspases).

Figure 4

Survivin plays a key role in DIM/butyrate-induced apoptosis

3,3′-Diindolylmethane down-regulates survivin and enhances butyrate-induced apoptosis in IMCE cells

To determine whether DIM can be effective when used in combination with butyrate for in vivo cancer prevention using APC^min/+ mice, we examined the effects of DIM/butyrate combination in IMCE cells. IMCE cells are colon epithelial cells derived from APC^min/+ mice, a mouse model widely used in colon cancer prevention research ⁴⁶. As shown in Figure 5A and 5B, DIM was able to down-regulate survivin in IMCE cells and significantly enhance butyrate-induce apoptosis in these cells. Comparing to HT-29 cells, caspase-3 and caspase-7 were activated by DIM/butyrate combination treatment in IMCE cells (Figure 5C), and potentially mediated apoptosis in these cells. We did not observe caspase-9 activation in these cells (data not shown). The different profiles of caspase activation between IMCE and HT-29 cells could be due to the different genetics of human and mouse cells. Thus, different caspases may mediate apoptosis between HT-29 and IMCE cells. Comparing to DIM-only treatment, the combination of DIM/butyrate did not further reduce the level of survivin protein (Figure 5C).

Figure 5

3,3′-Diindolylmethane down-regulates survivin and enhances butyrate-induced apoptosis in IMCE cells

3,3′-Diindolylmethane enhances butyrate-induced apoptosis and efficacy of cancer prevention in APC^min/+ mice

We tested whether the DIM/butyrate combination strategy can be applied in vivo for cancer prevention in APC^min/+ mice. First, we tested whether DIM can down-regulate survivin in vivo in APC^min/+ mice and determined the optimal dose of DIM. As shown in Figure 6A, oral administration of various doses of DIM was effective in down-regulating survivin protein in the intestinal tumors from APC^min/+ mice. The optimal dose was determined to be 10 mg/kg/day due to the solubility of DIM. No toxicities (body weight loss, etc) were observed at these doses. APC^min/+ mice were then randomly assigned to four groups and treated with DIM or butyrate alone, or DIM/butyrate combination. As shown in Figure 6B, treatment with DIM/butyrate combination significantly decreased tumors numbers in APC^min/+ mice. While butyrate-treated group has slightly decreased number of tumors, DIM alone has no effects on the number of tumors in these mice. To examine apoptosis in tumors, separate groups of mice were treated with doses and schedule as above and sacrificed immediately after drug treatment since apoptotic cells are cleared quickly in vivo. We performed in vivo TUNEL assay to determine the level of apoptosis in the tumors isolated from APC^min/+ mice. As shown in Figure 6C, significant higher levels of apoptosis were observed in the mice receiving DIM/butyrate combination treatment, comparing to the low levels of apoptosis in control group or mice receiving single drug treatment.

Figure 6

3,3′-Diindolylmethane enhances butyrate-induced apoptosis and efficacy of cancer prevention in APC^min/+ mice

Discussion

This study has provided strong support for a novel combination strategy of using 3,3′-Diindolylmethane and butyrate for colon cancer prevention. Short-chain fatty acids, mainly acetate, propionate, and butyrate, are produced during bacteria fermentation of resistant starch and nonstarch polysaccharides (major components of dietary fiber) in the human colon ⁴⁷. Butyrate is the major energy source for intestinal epithelial cells ⁴⁸. By promoting cell differentiation, cell-cycle arrest and apoptosis of transformed colonocytes ⁴⁹^-⁵¹, butyrate has been regarded as a cancer preventive agent and extensively evaluated for colon cancer prevention ⁵²^,⁵³. However, the effects of butyrate in prevention of animal models of colon cancer are often limited and in some cases butyrate even promotes tumor occurrence ¹¹^-¹³^,⁵⁴. Butyrate is an inhibitor of HDAC enzymes ³^,⁵⁵. We have recently demonstrated that APC mutations in colon cancer cells cause resistance to HDAC inhibitors in general due to a failure of survivin down-regulation ¹⁴. In the present study, we found that APC mutations also caused resistance to apoptosis in colon cancer cells treated with butyrate, as survivin was not down-regulated by butyrate in these cells. Thus, down-regulation of survivin is the key target to overcome colon cancer resistance to butyrate in cancer prevention.

DIM is a natural compound formed during the autolytic breakdown of glucobrassicin present in food plants of the Brassica genus, including broccoli, cabbage, Brussels sprouts, cauliflower and kale ⁵⁶. We found that DIM is very effective in down-regulating survivin and DIM is able to significantly potentiate butyrate-induced apoptosis in colon cancer cells expressing mutant APC. Although survivin is not the only target for DIM, our data indicate that down-regulation of survivin plays a key role in DIM-mediated effects on apoptosis. While overexpression of survivin blocked DIM/butyrate-induced apoptosis in HT-29 cells, knocking-down survivin protein by siRNA successfully bypassed the requirement of DIM and induced apoptosis after butyrate treatment (Figure 4). Other efforts have been developed to inhibit survivin by antisense and ribozymes ⁵⁷^-⁵⁹ and by using survivin mutants to suppress wild-type survivin ⁶⁰. However, as a non-toxic small molecule agent, DIM may prove to be more effective and safer for cancer prevention purpose.

We have previously demonstrated that HDAC inhibitors down-regulate survivin through a GSK-3β/β-catenin/Tcf-4 pathway which is dependent on the expression of wild-type APC ¹⁴. Thus, HT-29 cells were resistant to butyrate-induced apoptosis due to the mutations of APC. Here, we show that by down-regulating cyclin B1, DIM is able to cause survivin degradation through an alternative mechanism independent of the status of APC. This mechanism involves a decrease of survivin Thr34 phosphorylation and resulting destabilization of survivin, successfully bypassing the requirement of wild-type APC. Through this mechanism, DIM is able to promote survivin degradation in HT-29 cells.

Down-regulation of survivin in HT-29 cells by transfection of survivin-targeting siRNA is not enough to cause apoptosis in our experiments. Apparently, other changes that occurred in the colon cancer cells (inhibition of HDACs, activation of Bax and Bak, and release of Smac and cytochrome c) in response to DIM/butyrate treatment contribute to the increased induction of apoptosis (Figure 3). The decrease of survivin lowers the threshold for apoptosis induction. We found that activation of caspase-3, caspase-7, and caspase-9 is involved in DIM/butyrate-induced apoptosis in HT-29 and IMCE cells, further indicating a role for the mitochondria-mediated intrinsic pathway of apoptosis ⁶¹.

In this report, we demonstrated that DIM is not only effective in in vitro studies, but more importantly DIM is effective in enhancing butyrate-induced apoptosis and improving the efficacy of cancer prevention in APC^min/+ mice. We employed a three-dose schedule for DIM (one dose every other day, and one week treatment of butyrate in drinking water). By fine-tuning the doses of DIM and butyrate as well as the scheduling of treatment, further improvement on the efficacy of cancer prevention can be potentially achieved. Taken together, the present findings have important implications for the clinical use of butyrate in colon cancer prevention. Using DIM in combination with butyrate may prove to be an effective strategy for the prevention of colorectal cancers in patients.

Acknowledgments

This research was supported by Grants 1R03CA130062 and 5R21CA111765 from the National Cancer Institute and by Grant Number 2P20RR015566 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) and its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. The authors are thankful for Jodie Haring of Center for Protease Research (North Dakota State University) who provided help for real-time PCR. Dr. Bert Vogelstein is gratefully acknowledged for providing HT-29/APC and HT-29/β-Gal cells. We thank Dr. Robert H. Whitehead of Vanderbilt University for providing the IMCE cells.

References

1. Corpet DE, Pierre F. Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev. 2003;12:391–400. [PMC free article] [PubMed]

2. Corpet DE, Pierre F. How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. Eur J Cancer. 2005;41:1911–1922. [PubMed]

3. Dashwood RH, Myzak MC, Ho E. Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention? Carcinogenesis. 2006;27:344–349. [PMC free article] [PubMed]

4. Kuefer R, Hofer MD, Altug V, et al. Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer. 2004;90:535–541. [PMC free article] [PubMed]

5. Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000;403:41–45. [PubMed]

6. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1:194–202. [PubMed]

7. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell. 2003;4:13–18. [PubMed]

8. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 2000;92:1210–1216. [PubMed]

9. Hassig CA, Tong JK, Schreiber SL. Fiber-derived butyrate and the prevention of colon cancer. Chem Biol. 1997;4:783–789. [PubMed]

10. Kim YS, Milner JA. Dietary modulation of colon cancer risk. J Nutr. 2007;137:2576S–2579S. [PubMed]

11. Freeman HJ. Effects of differing concentrations of sodium butyrate on 1,2-dimethylhydrazine-induced rat intestinal neoplasia. Gastroenterology. 1986;91:596–602. [PubMed]

12. Caderni G, Luceri C, Lancioni L, Tessitore L, Dolara P. Slow-release pellets of sodium butyrate increase apoptosis in the colon of rats treated with azoxymethane, without affecting aberrant crypt foci and colonic proliferation. Nutr Cancer. 1998;30:175–181. [PubMed]

13. Caderni G, Luceri C, De Filippo C, et al. Slow-release pellets of sodium butyrate do not modify azoxymethane (AOM)-induced intestinal carcinogenesis in F344 rats. Carcinogenesis. 2001;22:525–527. [PubMed]

14. Huang X, Guo B. Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells. Cancer Res. 2006;66:9245–9251. [PubMed]

15. Levy DB, Smith KJ, Beazer-Barclay Y, Hamilton SR, Vogelstein B, Kinzler KW. Inactivation of both APC alleles in human and mouse tumors. Cancer Res. 1994;54:5953–5958. [PubMed]

16. Kikuchi-Yanoshita R, Konishi M, Fukunari H, Tanaka K, Miyaki M. Loss of expression of the DCC gene during progression of colorectal carcinomas in familial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Res. 1992;52:3801–3803. [PubMed]

17. Sidransky D, Tokino T, Hamilton SR, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science. 1992;256:102–105. [PubMed]

18. Shirasawa S, Urabe K, Yanagawa Y, Toshitani K, Iwama T, Sasazuki T. p53 gene mutations in colorectal tumors from patients with familial polyposis coli. Cancer Res. 1991;51:2874–2878. [PubMed]

19. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta. 2003;1653:1–24. [PubMed]

20. Behrens J, von Kries JP, Kuhl M, et al. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature. 1996;382:638–642. [PubMed]

21. Morin PJ. beta-catenin signaling and cancer. Bioessays. 1999;21:1021–1030. [PubMed]

22. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science. 1990;247:322–324. [PubMed]

23. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell. 2004;5:455–463. [PubMed]

24. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3:46–54. [PubMed]

25. Wheatley SP, Carvalho A, Vagnarelli P, Earnshaw WC. INCENP is required for proper targeting of Survivin to the centromeres and the anaphase spindle during mitosis. Curr Biol. 2001;11:886–890. [PubMed]

26. Gong Y, Sohn H, Xue L, Firestone GL, Bjeldanes LF. 3,3′-Diindolylmethane is a novel mitochondrial H(+)-ATP synthase inhibitor that can induce p21(Cip1/Waf1) expression by induction of oxidative stress in human breast cancer cells. Cancer Res. 2006;66:4880–4887. [PubMed]

27. Bhuiyan MM, Li Y, Banerjee S, et al. Down-regulation of androgen receptor by 3,3′-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res. 2006;66:10064–10072. [PubMed]

28. Kong D, Banerjee S, Huang W, et al. Mammalian target of rapamycin repression by 3,3′-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells. Cancer Res. 2008;68:1927–1934. [PubMed]

29. Chen Y, Xu J, Jhala N, et al. Fas-mediated apoptosis in cholangiocarcinoma cells is enhanced by 3,3′-diindolylmethane through inhibition of AKT signaling and FLICE-like inhibitory protein. Am J Pathol. 2006;169:1833–1842. [PubMed]

30. Kim EJ, Park SY, Shin HK, Kwon DY, Surh YJ, Park JH. Activation of caspase-8 contributes to 3,3′-Diindolylmethane-induced apoptosis in colon cancer cells. J Nutr. 2007;137:31–36. [PubMed]

31. Rahman KM, Ali S, Aboukameel A, et al. Inactivation of NF-kappaB by 3,3′-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. Mol Cancer Ther. 2007;6:2757–2765. [PubMed]

32. Rahman KW, Li Y, Wang Z, Sarkar SH, Sarkar FH. Gene expression profiling revealed survivin as a target of 3,3′-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res. 2006;66:4952–4960. [PubMed]

33. Kong D, Li Y, Wang Z, Banerjee S, Sarkar FH. Inhibition of angiogenesis and invasion by 3,3′-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res. 2007;67:3310–3319. [PubMed]

34. Morin PJ, Vogelstein B, Kinzler KW. Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci U S A. 1996;93:7950–7954. [PubMed]

35. Wolfensohn S, Lloyd M. Handbook of Laboratory Animal Management and Welfare. Blackwell; Oxford: 1998.

36. O'Connor DS, Grossman D, Plescia J, et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A. 2000;97:13103–13107. [PubMed]

37. Wall NR, O'Connor DS, Plescia J, Pommier Y, Altieri DC. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res. 2003;63:230–235. [PubMed]

38. Lindsten T, Ross AJ, King A, et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell. 2000;6:1389–1399. [PubMed]

39. Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 2001;292:727–730. [PubMed]

40. Chittenden T. BH3 domains: intracellular death-ligands critical for initiating apoptosis. Cancer Cell. 2002;2:165–166. [PubMed]

41. Gross A, Jockel J, Wei MC, Korsmeyer SJ. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. Embo J. 1998;17:3878–3885. [PubMed]

42. Guo B, Yin MB, Toth K, Cao S, Azrak RG, Rustum YM. Dimerization of mitochondrial Bax is associated with increased drug response in Bax-transfected A253 cells. Oncol Res. 1999;11:91–99. [PubMed]

43. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell. 1996;86:147–157. [PubMed]

44. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev. 2001;15:2922–2933. [PubMed]

45. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000;102:33–42. [PubMed]

46. Whitehead RH, Joseph JL. Derivation of conditionally immortalized cell lines containing the Min mutation from the normal colonic mucosa and other tissues of an “Immortomouse”/Min hybrid. Epithelial Cell Biol. 1994;3:119–125. [PubMed]

47. Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev. 2001;81:1031–1064. [PubMed]

48. Roediger WE. Utilization of nutrients by isolated epithelial cells of the rat colon. Gastroenterology. 1982;83:424–429. [PubMed]

49. Hague A, Manning AM, Hanlon KA, Huschtscha LI, Hart D, Paraskeva C. Sodium butyrate induces apoptosis in human colonic tumour cell lines in a p53-independent pathway: implications for the possible role of dietary fibre in the prevention of large-bowel cancer. Int J Cancer. 1993;55:498–505. [PubMed]

50. Heerdt BG, Houston MA, Augenlicht LH. Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. Cancer Res. 1994;54:3288–3293. [PubMed]

51. Heerdt BG, Houston MA, Augenlicht LH. Short-chain fatty acid-initiated cell cycle arrest and apoptosis of colonic epithelial cells is linked to mitochondrial function. Cell Growth Differ. 1997;8:523–532. [PubMed]

52. Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol. 2006;40:235–243. [PubMed]

53. Lupton JR. Microbial degradation products influence colon cancer risk: the butyrate controversy. J Nutr. 2004;134:479–482. [PubMed]

54. Zoran DL, Turner ND, Taddeo SS, Chapkin RS, Lupton JR. Wheat bran diet reduces tumor incidence in a rat model of colon cancer independent of effects on distal luminal butyrate concentrations. J Nutr. 1997;127:2217–2225. [PubMed]

55. Jung M. Inhibitors of histone deacetylase as new anticancer agents. Curr Med Chem. 2001;8:1505–1511. [PubMed]

56. Aggarwal BB, Ichikawa H. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle. 2005;4:1201–1215. [PubMed]

57. Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem. 1998;273:11177–11182. [PubMed]

58. Kanwar JR, Shen WP, Kanwar RK, Berg RW, Krissansen GW. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst. 2001;93:1541–1552. [PubMed]

59. Pennati M, Binda M, De Cesare M, et al. Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis. 2004;25:1129–1136. [PubMed]

60. Mesri M, Wall NR, Li J, Kim RW, Altieri DC. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest. 2001;108:981–990. [PMC free article] [PubMed]

61. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004;116:205–219. [PubMed]